Markers of endothelial damage and coagulation impairment in patients with severe sepsis resuscitated with hydroxyethyl starch 130/0.42 vs Ringer acetate

Journal of Critical Care

Volumn 32, Issue , 2016, Pages 16-20

  Müller, Rasmus Beier ^a   Ostrowski, Sisse Rye ^a   Haase, Nicolai ^a   Wetterslev, Jørn ^a   Perner, Anders ^a   Johansson, Pär Ingemar ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Colloids; Endothelial damage; Hydroxyethyl starch; Resuscitation; Severe sepsis

Indexed keywords

CD40 LIGAND; HETASTARCH; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; RINGER ACETATE; SYNDECAN 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER; HETASTARCH DERIVATIVE; ISOTONIC SOLUTION; PLASMA SUBSTITUTE; RINGER'S ACETATE; SERPINE1 PROTEIN, HUMAN; THBD PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; FLUID RESUSCITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); POST HOC ANALYSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS; BLOOD COAGULATION; FEMALE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; ISOTONIC SOLUTIONS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLASMA SUBSTITUTES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESUSCITATION; SEPSIS; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84959462782     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2015.11.025     Document Type: Article

References (40)

1. Perner A., Haase N., Guttormsen A.B., Tenhunen J., Klemenzson G., Åneman A., et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, 367:124-134.
2. Haase N., Wetterslev J., Winkel P., Perner A. Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med 2013, 39:2126-2134.
3. Müller R.B., Haase N., Lange T., Wetterslev J., Perner A. Acute kidney injury with hydroxyethyl starch 130/0.42 in severe sepsis. Acta Anaesthesiol Scand 2015, 59:329-336.
4. Goldenberg N.M., Steinberg B.E., Slutsky A.S., Lee W.L. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 2011, 3:88ps25.
5. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101:3765-3777.
6. Reinhart K., Bayer O., Brunkhorst F., Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002, 30:S302-S312.
7. Johansen M., Johansson P., Ostrowski S., Bestle M., Hein L., Jensen A., et al. Profound endothelial damage predicts impending organ failure and death in sepsis. Semin Thromb Hemost 2015, 41:16-25.
8. Shapiro N.I., Schuetz P., Yano K., Sorasaki M., Parikh S.M., Jones A.E., et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 2010, 14:R182.
9. Skibsted S., Jones A.E., Puskarich M.A., Arnold R., Sherwin R., Trzeciak S., et al. Biomarkers of endothelial cell activation in early sepsis. Shock 2013, 39:427-432.
10. Johansson P.I., Stensballe J., Rasmussen L.S., Ostrowski S.R. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011, 254:194-200.
11. Johansson P.I., Sørensen A.M., Perner A., Welling K.L., Wanscher M., Larsen C.F., et al. High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality. J Thromb Haemost 2012, 10:207-216.
12. Perner A., Haase N., Wetterslev J., Aneman A., Tenhunen J., Guttormsen A.B., et al. Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S-Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials 2011, 12:24.
13. Perner A., Haase N., Winkel P., Guttormsen A.B., Tenhunen J., Klemenzson G., et al. Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate. Intensive Care Med 2014, 40:927-934.
14. Müller R.G., Haase N., Wetterslev J., Perner A. Effects of hydroxyethyl starch in subgroups of patients with severe sepsis: exploratory post-hoc analyses of a randomised trial. Intensive Care Med 2013, 39:1963-1971.
15. Ostrowski S.R., Haase N., Müller R.B., Møller M.H., Pott F.C., Perner A., et al. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study. Crit Care 2015, 19:191.
16. Haase N., Ostrowski S.R., Wetterslev J., Lange T., Møller M.H., Tousi H., et al. Thromboelastography in patients with severe sepsis: a prospective cohort study. Intensive Care Med 2014, 41:77-85.
17. Johansson P.I., Haase N., Perner A., Ostrowski S.R. Association between sympathoadrenal activation, fibrinolysis and endothelial damage in septic patients: a prospective study. J Crit Care 2014, 29:327-333.
18. Blann A., Seigneur M. Soluble markers of endothelial cell function. Clin Hemorheol Microcirc 1997, 17:3-11.
19. Rehm M., Bruegger D., Christ F., Conzen P., Thiel M., Jacob M., et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007, 116:1896-1906.
20. Henn V., Slupsky J.R., Gräfe M., Anagnostopoulos I., Förster R., Müller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
21. Lowenstein C.J., Morrell C.N., Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005, 302-308.
22. Le Gall J.R., Lemeshow S., Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
23. Vincent J.L., de Mendonça A., Cantraine F., Moreno R., Takala J., Suter P.M., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800.
24. Schäper J., Ahmed R., Schäfer T., Elster A., Enigk F., Habazettl H., et al. Volume therapy with colloid solutions preserves intestinal microvascular perfusion in endotoxaemia. Resuscitation 2008, 76:120-128.
25. Jacob M., Bruegger D., Rehm M., Welsch U., Conzen P., Becker B.F. Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability. Anesthesiology 2006, 104:1223-1231.
26. Myburgh J.A., Finfer S., Bellomo R., Billot L., Cass A., Gattas D., et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012, 367:1901-1911.
27. Guidet B., Martinet O., Boulain T., Philippart F., Poussel J.F., Maizel J., et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 2012, 16:R94.
28. Zarychanski R., Abou-Setta A.M., Turgeon A.F., Houston B.L., McIntyre L., Marshall J.C., et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013, 309:678-688.
29. Perel P., Roberts I., Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013, 2:CD000567.
30. Gattas D.J., Dan A., Myburgh J., Billot L., Lo S., Finfer S. Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013, 39:558-568.
31. Haase N., Perner A., Hennings L.I., Siegemund M., Lauridsen B., Wetterslev M., et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013, 346:f839.
32. Johansson P.I., Stensballe J., Rasmussen L.S., Ostrowski S.R. High circulating adrenaline levels at admission predict increased mortality after trauma. J Trauma Acute Care Surg 2012, 72:428-436.
33. Ostrowski S.R., Sørensen A.M., Windeløv N.A., Perner A., Welling K.L., Wanscher M., et al. High levels of soluble VEGF receptor 1 early after trauma are associated with shock, sympathoadrenal activation, glycocalyx degradation and inflammation in severely injured patients: a prospective study. Scand J Trauma Resusc Emerg Med 2012, 20:27.
34. Lorente L., Martín M.M., Varo N., Borreguero-León J.M., Solé-Violán J., Blanquer J., et al. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Crit Care 2011, 15:R97.
35. Prakash S., Verghese S., Roxby D., Dixon D., Bihari S., Bersten A. Changes in fibrinolysis and severity of organ failure in sepsis: a prospective observational study using point-of-care test-ROTEM. J Crit Care 2015, 30:264-270.
36. Inglis T.J. Principia aetiologica: taking causality beyond Koch's postulates. J Med Microbiol 2007, 56:1419-1422.
37. Angus D.C., van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013, 369:840-851.
38. Vickers A.J., Altman D.G. Statistics notes: missing outcomes in randomised trials. BMJ 2013, 346:f3438.
39. Gluud C., Brok J., Gong Y., Koretz R.L. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007, 46:734-742.
40. Gluud C., Gluud L.L. Evidence based diagnostics. BMJ 2005, 330:724-726.